Endovia and Lupvindol announced the FDA has granted CannEpil minor-use status for bone cancer pain in dogs, allowing it to pursue conditional approval and targeting a 2027 commercial launch.
Endovia and Lupvindol announced the FDA has granted CannEpil minor-use status for bone cancer pain in dogs, allowing it to pursue conditional approval and targeting a 2027 commercial launch.